Dr. Reddys Labs (RDY) Reports Q3 EPS of $0.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Dr. Reddy’s Q3 and 9M FY16 Financial Results
February 9, 2016 4:55 AM EST
Q3 Revenues at Rs. 39.7 billion (YoY growth of 3%)
Q3
EBITDA at Rs. 10.1 billion (25.5% of the revenues)
9M Revenues at Rs. 117.1 billion (YoY growth of 7%)
9M
EBITDA at Rs. 31.4 billion (26.8% of the revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the quarter ended December 31, 2015 under International Financial Reporting Standards (IFRS).
Q3 FY16: Key Highlights
Consolidated revenues at Rs. 39.7 billion, year-on-year growth of 3%.... More